Skip to content

Feasibility of Thin Cp-EBUS Scope BF-UC290F for the Diagnosis of PPLs

Feasibility and Safety of Thin Convex Probe EBUS Scope BF-UC290F for the Diagnosis of Peripheral Pulmonary Lesions

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05512533
Enrollment
31
Registered
2022-08-23
Start date
2022-09-02
Completion date
2023-07-12
Last updated
2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Pulmonary Lesions

Keywords

EBUS-TBNA, diagnostic yield, peripheral pulmonary lesions (PPLs)

Brief summary

The purpose of the study is to evaluate the diagnostic value and safety of Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS) Scope for peripheral pulmonary lesions (PPLs)

Detailed description

This study will determine the feasibility of the novel thin convex probe endobronchial ultrasound (TCP-EBUS) Scope for the diagnosis of peripheral pulmonary lesions. The primary end point is to clarify the feasibility of using the thin convex probe EBUS scope to biopsy peripheral pulmonary lesions. The secondary objective is to evaluate operation time, sample adequacy, factors affecting the diagnosis rate, etc. The safety, insertion ability, and operability of the thin convex probe EBUS would also be evaluated.

Interventions

DEVICELinear Ultrasound Bronchoscope BF-UC290F (Olympus)

A thin Olympus EBUS bronchoscope BF-UC290F will be used for all endobronchial ultrasound examinations, and biopsies will be conducted with EBUS needles - the ViziShot 2 22G (Olympus).

Sponsors

Shanghai Chest Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients older than 18 years old. * Chest imaging shows the presence of peripheral pulmonary lesions (surrounded by pulmonary parenchyma and located below the segmental bronchus as seen radiographically.) suspicious of malignancy, 0.8-5cm in greatest diameter in need of bronchoscopic biopsy for clinical purposes, and the investigators consider it possible to be biopsied with BF-UC290F (the bronchus adjacent or leading to the PPLs are close to 5mm in diameter, thus BF-UC290F is able to arrival/access). * Patients without contraindications of bronchoscopy. * Patients have good medical adherence and signed informed consent.

Exclusion criteria

* Peripheral pulmonary lesion is pure ground-glass opacity. * Visible lumen lesions during bronchoscopy * The lesions were adjacent to the central airway (trachea, left and right main bronchus, and right middle bronchus), and the biopsies by the Thin Convex Probe EBUS Scope BF-UC290F were conducted without leaf bronchus entry * The investigators believe that patient has other conditions that are not suitable for the study.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic yield of BF-UC290F for PPLsUp to 6 monthsDiagnostic yield is defined as the proportion of peripheral pulmonary lesions (PPLs) diagnosed via endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in all lesions undergoing bronchoscopy biopsy via EBUS-TBNA.

Secondary

MeasureTime frameDescription
EBUS scope operation timeImmediately after each operationIt is defined as the total time from insertion of the EBUS scope to withdrawal of the EBUS scope
The total time of lesion accessImmediately after Each OperationIt is defined as the total time from the insertion of the EBUS scope to the arrival confirmed by ultrasound image.
The bronchus level of lesions, and the bronchus level reached with the EBUS scopeDuring the procedureLevel: Main bronchus is level 0, lobar bronchus is level 1, segment bronchus is level 2, sub-segment bronchus is level 3, and so on, such as: LB3a is level 3
Specimen adequacyUp to 6 monthsThe adequacy of specimens obtained by Thin Convex Probe EBUS Scope BF-UC290F for pathological typing, molecular testing, and immune checkpoint detection
Factors affecting the diagnosis rateUp to 6 monthsFactors affecting the diagnosis rate, including the nature of the lesions, the size of the lesions, the location of the lesions and so on will be analyzed.

Other

MeasureTime frameDescription
Safety Outcome: Complication rate1 monthThe complications refer to the total of serious adverse events related to the procedure during or within 1 month after the operation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026